Patents by Inventor Marianne L. JENSEN

Marianne L. JENSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20240026360
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
  • Oligonucleotides for modulating Tau expression
    Patent number: 11753640
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: September 12, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Anja Mølhart Høg, Richard E. Olson, Marianne L. Jensen
  • Oligonucleotides for modulating TMEM106B expression
    Patent number: 11485975
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Peter Hagedorn, Marianne L. Jensen, Lukasz Kielpinski, Amy Easton, Benny Chih
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20220177884
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: January 21, 2022
    Publication date: June 9, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. OLSON
  • Oligonucleotides for modulating Tau expression
    Patent number: 11279929
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 22, 2022
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Peter Hagedorn, Anja Mølhart Høg, Marianne L. Jensen, Richard E. Olson
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20210123054
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: December 31, 2020
    Publication date: April 29, 2021
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
  • OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
    Publication number: 20210054383
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 25, 2021
    Inventors: Peter HAGEDORN, Marianne L. JENSEN, Lukasz KIELPINSKI, Amy EASTON, Benny CHIH
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20200010831
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Applicant: Hoffmann-La Roche, Inc.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. Olson